5 Star
  • .

    Sign up for daily e-mails

    .
    .
    .

    United Press International is a leading provider of news, photos and information to millions of readers around the globe via UPI.com and its licensing services.

    With a history of reliable reporting dating back to 1907, today's UPI is a credible source for the most important stories of the day, continually updated - a one-stop site for U.S. and world news, as well as entertainment, trends, science, health and stunning photography. UPI also provides insightful reports on key topics of geopolitical importance, including energy and security.

    .

    But they were unsuccessful in their attempts and Charlie died last July, a week before his first birthday.

    He had suffered from a rare genetic condition called mitochondrial depletion syndrome, which causes progressive muscle weakness and brain damage.

    Mr Gard said that before his son's death he had promised the child he would "care for and look after" the youngster's mother.

    He wrote on Facebook: "Just a couple of hours before Charlie passed away, I laid on his bed, held his hand and had a little father/son chat with him.

    "I told him many things. I told him how much he was loved, how much he would be missed and how proud we all were of him, amongst lots of other things.

    "I also made a number of promises to him. Ones that I will never break. And one of those promises I made was that no matter what happens, I would always care for and look after his gorgeous mummy for him.

    .
    .

    NASHVILLE -- Among multiple sclerosis (MS) patients experiencing breakthrough disease on standard-dose once-a-week interferon beta 1-a (IFN-1α), switching to twice-weekly dosing may offer advantages, a researcher reported here.

    More than half of patients with breakthrough disease and adequate follow-up (26/52 patients) who were switched to twice-weekly treatment had no further clinical relapses, new T2 lesions, or enhanced lesions on MRI, or worsening of Expanded Disability Status Scale (EDSS) during at least 14 months (range 14 to 192 months) of follow-up, according to Robert Baumhefner, MD, of the VA Greater Los Angeles Healthcare System.

    . .